Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4,5 million patients worldwide regularly undergo dialysis treatment. We offer products and services along the entire dialysis value chain from a single source. As of December 31, 2025, we cared for more than 292,000 patients in our global network of roughly 3,600 dialysis centers worldwide. At the same time, we operated around 35 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables.
With decades of experience in dialysis care, we combine innovative technologies, high-quality treatment standards, and a patient-centered approach to improve outcomes and quality of life for patients worldwide. We are committed to advancing kidney care through innovation, operational excellence, and sustainable value creation for patients, healthcare systems, employees, and shareholders.
- <h3><span class="text-deep-blue">In-center HD</span></h3>
- <h3><span class="text-deep-blue">In-center HD</span></h3>
- <h3><span class="text-deep-blue">In-center HD</span></h3>
- <h3><span class="text-deep-blue">In-center HD</span></h3>
Global leader in kidney care
Differentiated vertically integrated business model with market-leading assets in the dialysis space:
- Care Delivery: a leading provider of kidney care services globally
- Value-Based Care: the number one U.S. renal value-based care provider
- Care Enablement: the number one global renal MedTech company
Care Delivery
Value-Based Care
Care Enablement
Note: MCUM = medical costs under management | Data as of FY 2025
Supportive underlying drivers within a growing chronic kidney disease market
FME Reignite strategy: We lead kidney care through exceptional patient care and innovation
Launched in 2025, FME Reignite marks the start of a new chapter for Fresenius Medical Care focused on accelerated innovation and growth, following a period of transformation in recent years.
Revenue growth (CAGR) between 2025 and 2030
| FY 2025 | Aspirations 2030 (at constant currencies) | |
Care Delivery | EUR 13,736 million | Low- to mid-single digit percent |
Care Enablement | EUR 5,476 million | Mid-single digit percent |
Value-Based Care is excluded
Operating income (CAGR) growth between 2025 and 2028
| Aspirations 2028 (at constant currencies) | |
Fresenius Medical Care Group | between 3 and 7 percent |
Operating income margin aspirations by 2030
| FY 2025 | Aspirations 2030 | |
Fresenius Medical Care Group | 11.3% | Mid-teens |
Care Delivery | 13.1% | Mid-teens |
Care Enablement | 8.1% | Mid-teens |
Value-Based Care | 0.1% | Low-single digit |
The assumed growth rates are at constant currency and exclude special items. The assumed margins exclude special items in operating income. Margin in percent of revenue.
Fresenius Medical Care is a highly cash generative business with strong operating cash flows of EUR 2.5 billion-plus.
Fresenius Medical Care has demonstrated strict financial discipline and clear focus to reignite shareholder value creation, while maintaining a solid balance sheet and a commitment to an investment grade credit rating.
This includes a dividend payout ratio of 30% to 40% adjusted net income and share buyback programs.